Psoriasiform dermatitis during dupilumab treatment for moderate‐to‐severe atopic dermatitis in children

Abstract

Although unusual, psoriasiform lesions can appear during effective treatment with dupilumab for atopic dermatitis, potentially reflecting a shift toward cutaneous IL-23/T_H 17 pathway activation with dupilumab-induced suppression of type 2 immunity.